The Motley Fool article’s author favors Pfizer as a 2026 pick over AbbVie, citing a 9.6 forward P/E versus AbbVie’s 18.8 and a stated 6% yield at Pfizer’s recent $28.50 share price, while acknowledging AbbVie’s strong growth case.
In FY 2025, AbbVie reported $61.2 billion in revenue, up 8.6%, and $4.3 billion in net income; Pfizer reported $62.6 billion in revenue, down 1.6%, and $7.8 billion in net income. Their price-to-sales ratios were 7.3 and 2.6, respectively; the article notes valuation figures may vary by provider.
Pfizer is working to offset declining demand for COVID-19 products and upcoming patent expirations by integrating acquisitions including Seagen and Metsera; it has 20 drug-development starts scheduled and expects eight data readouts in 2026. AbbVie’s growth is driven by Skyrizi and Rinvoq, but the article flags patent and biosimilar risks and U.S. drug-price setting. It also notes a possible FDA decision on an AbbVie Parkinson’s treatment later this year.
